Literature DB >> 15006138

Screening for presenilin inhibitors using the free-living nematode, Caenorhabditis elegans.

Brenda R Ellerbrock1, Eileen M Coscarelli, Mark E Gurney, Timothy G Geary.   

Abstract

Caenorhabditis elegans contains 3 homologs of presenilin genes that are associated with Alzheimer s disease. Loss-of-function mutations in C. elegans genes cause a defect in egg laying. In humans, loss of presenilin-1 (PS1) function reduces amyloid-beta peptide processing from the amyloid protein precursor. Worms were screened for compounds that block egg laying, phenocopying presenilin loss of function. To accommodate even relatively high throughput screening, a semi-automated method to quantify egg laying was devised by measuring the chitinase released into the culture medium. Chitinase is released by hatching eggs, but little is shed into the medium from the body cavity of a hermaphrodite with an egg laying deficient (egl) phenotype. Assay validation involved measuring chitinase release from wild-type C. elegans (N2 strain), sel-12 presenilin loss-of-function mutants, and 2 strains of C. elegans with mutations in the egl-36 K(+) channel gene. Failure to find specific presenilin inhibitors in this collection likely reflects the small number of compounds tested, rather than a flaw in screening strategy. Absent defined biochemical pathways for presenilin, this screening method, which takes advantage of the genetic system available in C. elegans and its historical use for anthelminthic screening, permits an entry into mechanism-based discovery of drugs for Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006138     DOI: 10.1177/1087057103261038

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  7 in total

1.  A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans.

Authors:  Shawn R Lockery; S Elizabeth Hulme; William M Roberts; Kristin J Robinson; Anna Laromaine; Theodore H Lindsay; George M Whitesides; Janis C Weeks
Journal:  Lab Chip       Date:  2012-05-15       Impact factor: 6.799

Review 2.  High-throughput screening and small animal models, where are we?

Authors:  Jean Giacomotto; Laurent Ségalat
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

3.  Specific conserved C-terminal amino acids of Caenorhabditis elegans HMP-1/α-catenin modulate F-actin binding independently of vinculin.

Authors:  Stephanie L Maiden; Neale Harrison; Jack Keegan; Brian Cain; Allison M Lynch; Jonathan Pettitt; Jeff Hardin
Journal:  J Biol Chem       Date:  2012-12-27       Impact factor: 5.157

4.  Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z.

Authors:  Sager J Gosai; Joon Hyeok Kwak; Cliff J Luke; Olivia S Long; Dale E King; Kevin J Kovatch; Paul A Johnston; Tong Ying Shun; John S Lazo; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

5.  Development and optimization of a high-throughput screening method utilizing Ancylostoma ceylanicum egg hatching to identify novel anthelmintics.

Authors:  Laura Abriola; Denton Hoyer; Conor R Caffrey; David L Williams; Timothy P Yoshino; Jon J Vermeire
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

6.  An ultra high-throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans.

Authors:  Chi K Leung; Ying Wang; Siobhan Malany; Andrew Deonarine; Kevin Nguyen; Stefan Vasile; Keith P Choe
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

7.  Modeling succinate dehydrogenase loss disorders in C. elegans through effects on hypoxia-inducible factor.

Authors:  Megan M Braun; Tamara Damjanac; Yuxia Zhang; Chuan Chen; Jinghua Hu; L James Maher
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.